Optimizing Post-CDK4/6i Strategies In HR +/HER2− Advanced Breast Cancer: A Contemporary Evidence-Based Framework
The advent of CDK4/6 inhibitors has transformed the frontline management of HR +/HER2− metastatic breast cancer. However, resistance to these agents is inevitable, leading to a growing need for evidence-based post-progression strategies. This review synthesizes data from major trials—SONIA, PALMIRA,...
Saved in:
| Main Authors: | Teena Rajan, Amol Akhade |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0045-1810005 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis
by: Yanrong Kang, et al.
Published: (2025-05-01) -
Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2− advanced or metastatic breast cancer in China
by: Caifeng Jia, et al.
Published: (2025-04-01) -
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
by: Paola Zagami, et al.
Published: (2025-02-01) -
An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial
by: Jiayu Wang, et al.
Published: (2025-06-01) -
QT STAR: concomitant QTc-prolonging medication use among patients with HR+/HER2− metastatic breast cancer receiving a CDK4/6 inhibitor in first line
by: Susan Dent, et al.
Published: (2025-07-01)